ES2483726T3 - Inhibidores de la P70 S6 quinasa - Google Patents

Inhibidores de la P70 S6 quinasa Download PDF

Info

Publication number
ES2483726T3
ES2483726T3 ES08747285.8T ES08747285T ES2483726T3 ES 2483726 T3 ES2483726 T3 ES 2483726T3 ES 08747285 T ES08747285 T ES 08747285T ES 2483726 T3 ES2483726 T3 ES 2483726T3
Authority
ES
Spain
Prior art keywords
phenyl
imidazol
trifluoromethyl
piperidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08747285.8T
Other languages
English (en)
Spanish (es)
Inventor
Robert Dean Dally
Jianping Huang
Sajan Joseph
Timothy Alan Shepherd
Christian L. Holst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2483726T3 publication Critical patent/ES2483726T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ES08747285.8T 2007-05-11 2008-05-01 Inhibidores de la P70 S6 quinasa Active ES2483726T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91733107P 2007-05-11 2007-05-11
US917331P 2007-05-11
PCT/US2008/062143 WO2008140947A1 (en) 2007-05-11 2008-05-01 P70 s6 kinase inhibitors

Publications (1)

Publication Number Publication Date
ES2483726T3 true ES2483726T3 (es) 2014-08-07

Family

ID=39765082

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08747285.8T Active ES2483726T3 (es) 2007-05-11 2008-05-01 Inhibidores de la P70 S6 quinasa

Country Status (34)

Country Link
US (2) US8093383B2 (pt)
EP (1) EP2148880B1 (pt)
JP (1) JP5503532B2 (pt)
KR (1) KR101088219B1 (pt)
CN (1) CN101679439B (pt)
AR (1) AR066344A1 (pt)
AU (1) AU2008251692B2 (pt)
BR (1) BRPI0811212A2 (pt)
CA (1) CA2687265C (pt)
CL (1) CL2008001230A1 (pt)
CO (1) CO6241109A2 (pt)
CR (1) CR11106A (pt)
DK (1) DK2148880T3 (pt)
DO (1) DOP2009000257A (pt)
EA (1) EA016445B1 (pt)
EC (1) ECSP099721A (pt)
ES (1) ES2483726T3 (pt)
GT (1) GT200900292A (pt)
HK (1) HK1140767A1 (pt)
HR (1) HRP20140611T1 (pt)
IL (1) IL201564A (pt)
MA (1) MA31433B1 (pt)
MX (1) MX2009012075A (pt)
MY (1) MY154898A (pt)
NZ (1) NZ580423A (pt)
PE (1) PE20090887A1 (pt)
PL (1) PL2148880T3 (pt)
PT (1) PT2148880E (pt)
RS (1) RS53451B (pt)
SI (1) SI2148880T1 (pt)
TN (1) TN2009000446A1 (pt)
TW (1) TWI423805B (pt)
UA (1) UA99284C2 (pt)
WO (1) WO2008140947A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US8252791B2 (en) * 2008-08-13 2012-08-28 Jenrin Discovery, Inc. Purine compounds as cannabinoid receptor blockers
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
BRPI0921840A2 (pt) * 2008-11-11 2018-10-09 Lilly Co Eli produto compreendendo o composto inibidor de p70 s6 quinase e inibidor de mtor, composto inibidor de p70 s6 quinase e uso do mesmo
KR20110075015A (ko) 2008-11-11 2011-07-05 일라이 릴리 앤드 캄파니 Ｐ70 ｓ6 키나제 억제제 및 ｅｇｆｒ 억제제 조합 요법
DK2396307T3 (en) 2009-02-11 2015-01-12 Merck Patent Gmbh NOVEL AMINO-azaheterocyclic carboxamides
WO2011017009A1 (en) 2009-08-07 2011-02-10 Merck Patent Gmbh Novel azaheterocyclic compounds
EA020151B1 (ru) * 2009-10-23 2014-09-30 Эли Лилли Энд Компани Ингибиторы akt и фармацевтические составы, их содержащие
CN102821767A (zh) 2010-02-03 2012-12-12 西格诺药品有限公司 Lkb1突变作为对tor激酶抑制剂的敏感性的预测生物标记的鉴定
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
JP5897590B2 (ja) 2010-11-24 2016-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナゾリンカルボキサミドアゼチジン
MX347241B (es) 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
SI2755965T1 (sl) * 2011-09-12 2017-12-29 Merck Patent Gmbh Novi imidazolni amidi kot modulatorji kinazne aktivnosti
US10227357B2 (en) 2012-09-06 2019-03-12 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
JP6280130B2 (ja) * 2012-11-16 2018-02-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
JP6290917B2 (ja) 2012-11-29 2018-03-07 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ アザキナゾリンカルボキサミド誘導体
WO2014143612A1 (en) * 2013-03-11 2014-09-18 Merck Patent Gmbh 6-[4-(1 h-imidazol-2-yl)piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
PE20160041A1 (es) 2013-04-17 2016-01-28 Signal Pharm Llc FORMULACIONES FARMACEUTICAS, PROCESO, FORMAS SOLIDAS Y METODOS DE USO RELACIONADOS CON 1-ETIL-7-(2-METIL-6-(1H-1,2,4-TRIAZOL-3-IL)PIRIDIN-3-IL)-3,4-DIHIDROPIRAZINO[2,3-b]PIRAZIN-2(1H)-ONA
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
TW201521725A (zh) 2013-04-17 2015-06-16 Signal Pharm Llc 使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
TWI631950B (zh) 2013-04-17 2018-08-11 標誌製藥公司 藉二氫吡𠯤并吡𠯤治療癌症
EP2986321A1 (en) 2013-04-17 2016-02-24 Signal Pharmaceuticals, LLC Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
CA2908957C (en) 2013-04-17 2021-05-18 Signal Pharmaceuticals, Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
CA2909625C (en) 2013-04-17 2021-06-01 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
WO2015134536A1 (en) * 2014-03-04 2015-09-11 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
EP3125935B1 (en) 2014-04-03 2019-10-23 Merck Patent GmbH Combinations of cancer therapeutics
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
WO2016040078A1 (en) * 2014-09-10 2016-03-17 Eli Lilly And Company Substituted phenyl imidazolyl piperidyl compounds as p70s6k1 inhibitors
US10160755B2 (en) 2015-04-08 2018-12-25 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
SG11201912403SA (en) 2017-06-22 2020-01-30 Celgene Corp Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
MX2023005520A (es) 2020-11-16 2023-05-23 Merck Patent Gmbh Combinaciones de inhibidores de cinasa para tratamiento de cancer.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1004346C2 (nl) 1996-10-23 1998-04-24 Dsm Nv Werkwijze voor het scheiden van een mengsel van enantiomeren in een geschikt oplosmiddel.
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2005117909A2 (en) * 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
CA2590961C (en) 2004-12-28 2013-11-26 Exelixis, Inc. [1h-pyrazolo[3,4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
US20090325924A1 (en) 2005-06-30 2009-12-31 Stuart Edward GPCR Agonists
JP5606734B2 (ja) 2006-04-25 2014-10-15 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2007125310A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Pharmaceutical combinations of pk inhibitors and other active agents
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
AR064416A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
UA99284C2 (ru) * 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ

Also Published As

Publication number Publication date
EA016445B1 (ru) 2012-05-30
KR20100005710A (ko) 2010-01-15
BRPI0811212A2 (pt) 2014-10-29
TN2009000446A1 (en) 2011-03-31
DOP2009000257A (es) 2010-03-31
GT200900292A (es) 2011-06-24
MA31433B1 (fr) 2010-06-01
US8093383B2 (en) 2012-01-10
JP5503532B2 (ja) 2014-05-28
HK1140767A1 (en) 2010-10-22
TWI423805B (zh) 2014-01-21
CA2687265C (en) 2012-12-04
ECSP099721A (es) 2009-12-28
JP2010526814A (ja) 2010-08-05
CA2687265A1 (en) 2008-11-20
EP2148880A1 (en) 2010-02-03
MY154898A (en) 2015-08-28
PE20090887A1 (es) 2009-07-13
RS53451B (en) 2014-12-31
AU2008251692B2 (en) 2012-10-11
CO6241109A2 (es) 2011-01-20
EA200971051A1 (ru) 2010-06-30
IL201564A0 (en) 2010-05-31
PL2148880T3 (pl) 2014-10-31
CL2008001230A1 (es) 2009-05-22
CR11106A (es) 2010-04-12
NZ580423A (en) 2012-02-24
HRP20140611T1 (hr) 2014-08-15
PT2148880E (pt) 2014-08-28
CN101679439A (zh) 2010-03-24
EP2148880B1 (en) 2014-05-28
US20090163714A1 (en) 2009-06-25
US20120071490A1 (en) 2012-03-22
DK2148880T3 (da) 2014-06-16
AU2008251692A1 (en) 2008-11-20
AR066344A1 (es) 2009-08-12
CN101679439B (zh) 2013-09-11
KR101088219B1 (ko) 2011-11-30
MX2009012075A (es) 2009-11-19
WO2008140947A1 (en) 2008-11-20
TW200848053A (en) 2008-12-16
UA99284C2 (ru) 2012-08-10
SI2148880T1 (sl) 2014-07-31
IL201564A (en) 2014-08-31

Similar Documents

Publication Publication Date Title
ES2483726T3 (es) Inhibidores de la P70 S6 quinasa
ES2796377T3 (es) Derivados de piperidin-4-IL azetidina como inhibidores de JAK1
ES2391704T3 (es) Inhibidores de cinasa AKT y P70 S6
EP2943485B1 (en) Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
WO2017207387A1 (en) Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
BR112017020900B1 (pt) Compostos de 1-ciano-pirrolidina como inibidores de usp30 e seu uso, composição farmacêutica
MX2012005100A (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3.
CA2778291A1 (en) Akt inhibitors
AU2019232437A1 (en) Identification and use of ERK5 inhibitors
CA3122136A1 (en) Tyrosine kinase inhibitors, compositions and methods there of
JP2023062074A (ja) Ｂ－ｒａｆキナーゼ阻害物質の結晶塩
JP2024502258A (ja) Ｃｇａｓに関連する状態の処置に有用なインドール誘導体
EP4069369A1 (en) Cyclic compounds and methods of using same
CN111825719A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
CA3022758C (en) Treatment of skin lesions
CN116490507A (zh) 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2023185073A1 (zh) Parp7抑制剂及其用途
KR20230172490A (ko) 사이클릭 화합물 및 이를 사용하는 방법
CN115504980A (zh) 嘧啶并含氮六元芳香杂环类化合物及其用途